C12N 2740/16271
Demonstrated in vivo effect
C12N2740/16271 (Demonstrated in vivo effect) appears on 25 US grants and 39 published applications in this corpus.
Search patents in C12N- Granted patents
- 25
- Published applications
- 39
- Assignees
- 37
- Inventors
- 82
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 2 |
| 2012 | 0 | 1 |
| 2013 | 1 | 0 |
| 2014 | 0 | 2 |
| 2015 | 1 | 1 |
| 2016 | 2 | 5 |
| 2017 | 5 | 10 |
| 2018 | 0 | 3 |
| 2019 | 7 | 6 |
| 2020 | 4 | 1 |
| 2021 | 2 | 1 |
| 2022 | 1 | 1 |
| 2023 | 0 | 3 |
| 2024 | 0 | 1 |
| 2025 | 0 | 1 |
| 2026 | 2 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for inducing an immune response using conserved element constructs18 Aug 2026US 12,709,635 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Persistent memory T-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways24 Mar 2026US 12,582,709 B2The Regents of the University of California
- Antiviral vaccines with improved cellular immunogenicity17 May 2022US 11,331,386 B2Beth Israel Deaconess Medical Center, Inc.
- Altering the immundominance hierarchy using a DNA vaccine expressing conserved regions9 Nov 2021US 11,167,025 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Vaccines with biomolecular adjuvants8 Jun 2021US 11,027,011 B2The Trustees of the University of Pennsylvania
- Immunogens and methods for inducing an immune response27 Nov 2025US 2025/0360199 A1
- Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection22 Aug 2024US 2024/0277829 A1The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Methods and compositions for inducing an immune response using conserved element constructs26 Oct 2023US 2023/0340029 A1The United States of America, as represented by the Secretary, Department of
- Persistent memory t-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways8 Jun 2023US 2023/0173056 A1The Regents of the University of California
- Chimpanzee adenovirus constructs with lyssavirus antigens25 May 2023US 2023/0158134 A1Glaxosmithkline Biologicals SA
Most cited
By later US patents
- Method for inducing a multiclade immune response against HIV utilizing a multigene and multiclade immunogen63US 8,454,972 B2GenVec, Inc. · 2013
- Antiviral vaccines with improved cellular immunogenicity48US 9,017,691 B2Beth Israel Deaconess Medical Center, Inc. · 2015
- Compositions and methods for the treatment of viral infections5US 9,290,545 B2Dana-Farber Cancer Institute, Inc. · 2016
- Compositions and methods comprising hydrocarbon-stapled polypeptides4US 10,259,848 B2Dana-Farber Cancer Institute, Inc. · 2019
- Antiviral vaccines with improved cellular immunogenicity4US 9,670,253 B2Beth Israel Deaconess Medical Center, Inc. · 2017